4//SEC Filing
Sucampo Pharmaceuticals, Inc. 4
Accession 0001171843-14-000871
CIK 0001365216operating
Filed
Feb 20, 7:00 PM ET
Accepted
Feb 21, 3:57 PM ET
Size
8.4 KB
Accession
0001171843-14-000871
Insider Transaction Report
Form 4
Dolecek Gayle R
DirectorVP of Research & Development
Transactions
- Exercise/Conversion
Class A Common Stock
2014-02-18$4.41/sh+9,067$39,985→ 9,067 total - Sale
Class A Common Stock
2014-02-18$8.04/sh−9,067$72,899→ 0 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2014-02-18−9,067→ 314,567 totalExercise: $4.41From: 2013-05-02Exp: 2021-05-02→ Class A Common Stock (9,067 underlying)
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the reporting person on June 13, 2013
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.14, inclusive. The reporting person undertakes to provide Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Issuer
Sucampo Pharmaceuticals, Inc.
CIK 0001365216
Entity typeoperating
Related Parties
1- filerCIK 0001365216
Filing Metadata
- Form type
- 4
- Filed
- Feb 20, 7:00 PM ET
- Accepted
- Feb 21, 3:57 PM ET
- Size
- 8.4 KB